Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | EVP, Europe Commercial | May 05, 2026 | May 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date May 05, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 55,755 |
Reported balance
After 2026-05-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-05 · Sale · Disposed 30,000 · Balance 55,755 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2024 Filed Mar 7, 2024 21:20 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 55,226 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-027986 · ownership.xml · nonDerivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 21:20 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 22,576 | $13.52 | $305,123.67 |
DisclosureSEC source: 0000950170-24-027986 · ownership.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,770 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.41 to $13.61, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 21:20 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 22,576 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-027986 · ownership.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:21 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 81,845 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025982 · ownership.xml · derivative · entry 7 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,845 Underlying: Ordinary Shares · 81,845 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 20,461 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 20,462 vesting on March 4, 2028. F7 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 20,461 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 20,462 vesting on March 4, 2028. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:21 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 33,512 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025982 · ownership.xml · derivative · entry 6 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,024 Underlying: Ordinary Shares · 33,512 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023 and March 4, 2024, and 33,512 vesting on each of March 4, 2025 and March 4, 2026. F6 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023 and March 4, 2024, and 33,512 vesting on each of March 4, 2025 and March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:21 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 33,512 | $13.34 | $446,959.60 |
DisclosureSEC source: 0000950170-24-025982 · ownership.xml · nonDerivative · entry 4 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,770 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $13.445, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:21 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 33,512 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-025982 · ownership.xml · nonDerivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:21 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 62,250 | $13.34 | $830,246.93 |
DisclosureSEC source: 0000950170-24-025982 · ownership.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,770 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $13.445, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:21 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 62,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025982 · ownership.xml · derivative · entry 5 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 186,753 Underlying: Ordinary Shares · 62,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 62,250 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 62,253 vesting on March 3, 2027. F5 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 62,250 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 62,253 vesting on March 3, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:21 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 62,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-025982 · ownership.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 11:43 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 20,599 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-023522 · ownership.xml · derivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 20,599 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 20,598 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 20,599 vested on February 28, 2024. F5 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 20,598 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 20,599 vested on February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 11:43 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 20,599 | $13.12 | $270,176.48 |
DisclosureSEC source: 0000950170-24-023522 · ownership.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,770 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.01 to $13.19, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 11:43 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 20,599 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-023522 · ownership.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,369 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 12:28 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 55,226 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-009616 · ownership.xml · derivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,226 Underlying: Ordinary Shares · 55,226 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 5, 2024. F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 5, 2024. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 07, 2023 Filed Mar 8, 2023 21:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 54,007 | $9.43 | $509,172.60 |
DisclosureSEC source: 0001209191-23-017154 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,770 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.37 to $9.725, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 21:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 18,002 | $9.93 | $178,776.06 |
DisclosureSEC source: 0001209191-23-017154 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,777 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $10.045, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2023 Filed Mar 7, 2023 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 22,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016686 · doc4.xml · derivative · entry 7 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,152 Underlying: Ordinary Shares · 22,576 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 22,576 vested on each of March 5, 2022 and March 5, 2023, and 22,576 vesting on each of March 5, 2024 and March 5, 2025. F6 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 22,576 vested on each of March 5, 2022 and March 5, 2023, and 22,576 vesting on each of March 5, 2024 and March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2023 Filed Mar 7, 2023 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 22,576 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016686 · doc4.xml · nonDerivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 33,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016686 · doc4.xml · derivative · entry 6 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,536 Underlying: Ordinary Shares · 33,512 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023, and 33,512 vesting on each of March 4, 2024, March 4, 2025 and March 4, 2026. F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023, and 33,512 vesting on each of March 4, 2024, March 4, 2025 and March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 15,921 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016686 · doc4.xml · derivative · entry 5 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,921 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 15,920 vested on each of March 4, 2021 and March 4, 2022, and 15,921 vested on March 4, 2023. F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 15,920 vested on each of March 4, 2021 and March 4, 2022, and 15,921 vested on March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 33,512 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016686 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 15,921 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016686 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 249,003 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016686 · doc4.xml · derivative · entry 4 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,003 Underlying: Ordinary Shares · 249,003 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 62,250 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 62,253 vesting on March 3, 2027. F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 62,250 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 62,253 vesting on March 3, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 12:33 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 50,242 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014435 · doc4.xml · derivative · entry 6 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 50,242 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on February 7, 2023 pursuant to the satisfaction of performance criteria and vested on February 28, 2023. F7 · derivative.expiration_date: Restricted share units were granted on February 7, 2023 pursuant to the satisfaction of performance criteria and vested on February 28, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 12:33 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 20,598 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014435 · doc4.xml · derivative · entry 5 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,599 Underlying: Ordinary Shares · 20,598 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 20,598 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 20,599 vesting on February 28, 2024. F6 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 20,598 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 20,599 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 12:33 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 23,654 | $9.89 | $233,857.64 |
DisclosureSEC source: 0001209191-23-014435 · doc4.xml · nonDerivative · entry 4 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,770 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $9.94, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 12:33 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 50,242 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-014435 · doc4.xml · nonDerivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 12:33 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 20,598 | $9.89 | $203,644.19 |
DisclosureSEC source: 0001209191-23-014435 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,182 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $9.94, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 12:33 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 20,598 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-014435 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 12:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 50,242 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007949 · doc4.xml · derivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,242 Underlying: Ordinary Shares · 50,242 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 28, 2023. F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 28, 2023. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 22,576 | $7.37 | $166,310.62 |
DisclosureSEC source: 0001209191-22-017034 · doc4.xml · nonDerivative · entry 6 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,182 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.49, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2022 Filed Mar 8, 2022 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 22,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017034 · doc4.xml · derivative · entry 10 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,728 Underlying: Ordinary Shares · 22,576 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F10 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 22,576 having vested on March 5, 2022 and 22,576 vesting on each of March 5, 2023, March 5, 2024 and March 5, 2025. F10 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 22,576 having vested on March 5, 2022 and 22,576 vesting on each of March 5, 2023, March 5, 2024 and March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2022 Filed Mar 8, 2022 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 22,576 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-017034 · doc4.xml · nonDerivative · entry 5 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 134,048 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017034 · doc4.xml · derivative · entry 9 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,048 Underlying: Ordinary Shares · 134,048 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F9 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026. F9 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 43,358 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017034 · doc4.xml · derivative · entry 8 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 43,358 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F8 · derivative.exercise_date: Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022. F8 · derivative.expiration_date: Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 15,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017034 · doc4.xml · derivative · entry 7 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,921 Underlying: Ordinary Shares · 15,920 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 15,920 having vested on each of March 4, 2021 and March 4, 2022, and 15,921 vesting on March 4, 2023. F7 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 15,920 having vested on each of March 4, 2021 and March 4, 2022, and 15,921 vesting on March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 20,456 | $7.48 | $153,062.02 |
DisclosureSEC source: 0001209191-22-017034 · doc4.xml · nonDerivative · entry 4 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,182 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 43,358 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-017034 · doc4.xml · nonDerivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 15,920 | $7.48 | $119,121.40 |
DisclosureSEC source: 0001209191-22-017034 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,280 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 15,920 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-017034 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 12:41 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 20,598 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014466 · doc4.xml · derivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,197 Underlying: Ordinary Shares · 20,598 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on February 28, 2020, with 20,598 having vested on each of February 28, 2021 and February 28, 2022, 20,598 vesting on February 28, 2023, and 20,599 vesting on February 28, 2024. F5 · derivative.expiration_date: Restricted share units were granted on February 28, 2020, with 20,598 having vested on each of February 28, 2021 and February 28, 2022, 20,598 vesting on February 28, 2023, and 20,599 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 12:41 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 20,598 | $8.14 | $167,713.04 |
DisclosureSEC source: 0001209191-22-014466 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,280 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.035 to $8.255, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 12:41 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 20,598 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-014466 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 13,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008409 · doc4.xml · derivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 13,135 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 13,135 having vested on each of February 9, 2020, February 9, 2021 and February 9, 2022. F5 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 13,135 having vested on each of February 9, 2020, February 9, 2021 and February 9, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 13,135 | $9.06 | $119,009.67 |
DisclosureSEC source: 0001209191-22-008409 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,280 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.06 to $9.075, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 13,135 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-008409 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 43,358 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008409 · doc4.xml · derivative · entry 4 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,358 Underlying: Ordinary Shares · 43,358 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022. F6 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 21:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 90,304 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018508 · doc4.xml · derivative · entry 4 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,304 Underlying: Ordinary Shares · 90,304 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 22,576 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and March 5, 2025. F7 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 22,576 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 15,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018508 · doc4.xml · derivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,841 Underlying: Ordinary Shares · 15,920 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 15,920 vesting on each of March 4, 2021 and March 4, 2022 and 15,921 vesting on March 4, 2023. F6 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 15,920 vesting on each of March 4, 2021 and March 4, 2022 and 15,921 vesting on March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 7,513 | $10.58 | $79,520.60 |
DisclosureSEC source: 0001209191-21-018508 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,280 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.510 to $10.700, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.